1. Home
  2. LGCL vs RNTX Comparison

LGCL vs RNTX Comparison

Compare LGCL & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCL
  • RNTX
  • Stock Information
  • Founded
  • LGCL 2009
  • RNTX 2001
  • Country
  • LGCL China
  • RNTX United States
  • Employees
  • LGCL N/A
  • RNTX N/A
  • Industry
  • LGCL
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGCL
  • RNTX Health Care
  • Exchange
  • LGCL NYSE
  • RNTX Nasdaq
  • Market Cap
  • LGCL 47.7M
  • RNTX 40.3M
  • IPO Year
  • LGCL 2024
  • RNTX N/A
  • Fundamental
  • Price
  • LGCL $1.07
  • RNTX $1.56
  • Analyst Decision
  • LGCL
  • RNTX
  • Analyst Count
  • LGCL 0
  • RNTX 0
  • Target Price
  • LGCL N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • LGCL 277.5K
  • RNTX 33.4K
  • Earning Date
  • LGCL 01-01-0001
  • RNTX 08-13-2025
  • Dividend Yield
  • LGCL N/A
  • RNTX N/A
  • EPS Growth
  • LGCL N/A
  • RNTX N/A
  • EPS
  • LGCL 0.07
  • RNTX N/A
  • Revenue
  • LGCL $145,690,427.00
  • RNTX N/A
  • Revenue This Year
  • LGCL N/A
  • RNTX N/A
  • Revenue Next Year
  • LGCL N/A
  • RNTX N/A
  • P/E Ratio
  • LGCL $9.92
  • RNTX N/A
  • Revenue Growth
  • LGCL N/A
  • RNTX N/A
  • 52 Week Low
  • LGCL $0.28
  • RNTX $1.35
  • 52 Week High
  • LGCL $3.31
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • LGCL N/A
  • RNTX N/A
  • Support Level
  • LGCL N/A
  • RNTX N/A
  • Resistance Level
  • LGCL N/A
  • RNTX N/A
  • Average True Range (ATR)
  • LGCL 0.00
  • RNTX 0.00
  • MACD
  • LGCL 0.00
  • RNTX 0.00
  • Stochastic Oscillator
  • LGCL 0.00
  • RNTX 0.00

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: